Fluzone Trivalent Northern Hemisphere Injection, Suspension
NDC 49281-645
Product Information
Fluzone Trivalent Northern Hemisphere (influenza a virus a/switzerland/6849/2025 ivr-278 (h1n1) antigen (formaldehyde inactivated), influenza a virus a/michigan/105/2025 san-049a (h3n2) antigen (formaldehyde inactivated), and influenza b virus b/tokyo/eis13-175/2025 antigen (formaldehyde inactivated)) is a BLA-approved product labeled by Sanofi Vaccines Us Inc.. This product is primarily utilized in pharmaceutical processing or compounding. It is supplied as a injection, suspension for intramuscular administration. This product entry covers the primary NDC 49281-645 and its associated package configuration. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Clinical Specifications
Labeler & Regulatory Data
Marketing Timeline
Code Structure Chart
Product Details
What is NDC 49281-645?
What are the uses of this product?
What are Active Ingredients of this product?
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 2746456 - influenza virus vaccine 2026-2027 (trivalent - Michigan/Switzerland/Tokyo) Injectable Suspension
- RxCUI: 2746456 - influenza A virus A/Michigan/105/2025 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Switzerland/6849/2025 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Tokyo/EIS13-175/2025 antigen 0.03 MG/ML Injectable Suspension
- RxCUI: 2746462 - Fluzone 2026-2027 trivalent vaccine Injectable Suspension
- RxCUI: 2746462 - influenza A virus A/Michigan/105/2025 (H3N2) antigen 0.03 MG/ML / influenza A virus A/Switzerland/6849/2025 (H1N1) antigen 0.03 MG/ML / influenza B virus B/Tokyo/EIS13-175/2025 antigen 0.03 MG/ML Injectable Suspension [Fluzone 2026-2027]
- RxCUI: 2746464 - influenza virus vaccine 2026-2027 (trivalent - Michigan/Switzerland/Tokyo) 0.5 ML Prefilled Syringe
* Please review the full disclaimer at the bottom of this page.